tbuckley/cabot-search huggingface dataset:
Abdominal Surgery.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial board
Authors: James Field, Samuel Soskin, Beverly Hills, Garfield Duncan, Hisham Barakat, George Bray, Jorge Calles-Escandon, Jose ´caro, M Charles, George Chrousos, Bernard Bethesda, St Davis, Leslie Louis, Frederick Degroot, Mario Derubertis, Atlanta Digirolamo, William Ga, Louis Duckworth, John Elsas, Kenneth Fain, San Feingold, Irving Francisco, Andrew Fox, New Frantz, Saul York, Henry Cleveland, New Ginsberg, Charles York, Abbas Glueck, Fredric Kitabchi, Stanford Kraemer, Nelly Mauras, James May, Donald Mcnamara, Glenn Mortimore, Maria New, New York, Caroline Pace, Michael Pagliassotti, William Denver, Alan Richmond, Los Robinson, Stanton Angeles, Peter Segal, Richard Stacpoole, Marc Durham, John Tucson
Journal: Metabolism (2003)
THE ELECTROCARDIOGRAM: A REAPPRAISAL
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0054 Immunological Properties of Synovial Fluid-Derived Mesenchymal Stem Cell-Like Cells in Rheumatoid Arthritis
Authors: Z. Veréb, A. Váncsa, M. Pilling, G. Petrovski, Έ. Rajnavölgyi, Z. Szekanecz
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Mesenchymal stem cells (MSC) are the stromal cells of bone marrow, but they can also be found in other tissues including the synovia. <h3>Objectives</h3> Our goal was to isolate and cultivate human synovial fluid-derived MSC-like cells (SYF-MSC) and study their role in immunity and angiogenesis with relevance to rheumatoid arthritis (RA). <h3>Methods</h3> Synovial fluid was harvested from patients with active RA (according to the Guidelines of the Helsinki Declaration). The isolated fluid/cells were cultured <i>in vitro,</i> and the expression of well-known MSC, hematopoietic, endothelial markers as well as high-end glycosylation products were measured by flow cytometry. <i>In vitro</i> differentiation assays were used to determine the stemness of SYF-MSCs. The immunosuppressive function of these cells was studied by mitogen-activated lymphocyte reaction, and their immunophenotype was investigated by cell activation with TLR ligands and pro-inflammatory cytokines; the secreted cytokines were measured by ELISA. <h3>Results</h3> The cells isolated from synovial fluid of patients with RA grew as monolayers <i>in vitro</i> and could be maintained in culture for more than 10 passages. The cells expressed the most important MSC markers (CD44, CD73, CD90 and CD105) with absence of endothelial (CD31, VEGFR2) or hematopoietic cell markers (CD34, CD45, CD69, CD133), respectively. SYF-MSCs were able to differentiate into bone, fat and cartilage tissue <i>in vitro</i> fulfilling the ISCT criteria, and could suppress the proliferation of mitogen activated peripheral blood lymphocytes. Furthermore, SYF-MSCs secreted increased amount of IL-6 after 12 and 24 hrs treatment by LPS (15423.61±9348.61 pg/ml at 12h; 17479.17±3848.63 pg/ml at 24h time points), Poly:IC (15215.28±10834.72 and 24090.28±3626.40 pg/ml), TNFα (7437.5±1168.06 and 11562.5±845.83 pg/ml) and IL-1β (19465.28±2306.94 and 21229.17±12.5 pg/ml) compared to untreated controls (1590.28±1015.28 and 2187.50±640.28 pg/ml), respectively. IL-8 could be detected in the supernatants of SYF-MSC only upon LPS (10876.76±7553.24 and 12117.94±2912.06 pg/ml), Poly:IC (8972.35±8707.65 and 30567.94±3637.94 pg/ml) TNFα (5516.47±1336.47 and 110325.29±5645.29 pg/ml) and IL-1β (18063.53±3083.53 and 24970.88±9940.88 pg/ml) treatment, but not in the untreated controls. <h3>Conclusions</h3> The <i>in vitro</i> data suggest that SYF-MSC may play a role in the inflammatory processes of RA, and their activation could lead to the release of pro-angiogenic cytokines as well. <h3>Disclosure of Interest</h3> None declared
Lectures on the Experimental Investigation of the Action of Medicines
Authors: T. L. Brunton
Journal: BMJ (1871)

Steps of an Intvestigation.-Admtinistrations of Drugs.-Observation of Effecs.-Interpretation of Results.-Ainimum hstal Dose.-Vizrious Channels of Admiiistration.-Excretioni.-Mode of securitngAnirnals.-IZstrumentsrequired.-Alodeofmakih,g Cannulte, T-tubes, and I'ns.-NAar- cotising Aninzals
Glaucoma
Authors: Thom J. Zimmerman
Journal: JAMA (1980)

This second edition of a classic text should be required reading for anyone interested in ophthalmology. Like the first, it is an excellent blend of clinical savvy supported by basic and clinical research. The preface to the first edition (1965) states that the senior author (PAC) has been giving lectures on glaucoma treatment for 30 years and the junior author has carried on laboratory and clinical investigations concerning glaucoma for 25 years. This edition is meticulously updated and supplemented with a smooth blend of new information by junior collaborators who are wellknown and respected glaucoma experts in their own right. The book is written as a practical guide for the diagnosis and treatment of various forms of glaucoma and for the solution of the problems encountered. Case presentations punctuate the information and make the book extremely readable. The complete tables are perfect for a quick review or for picking up
BOOK REVIEWS
Authors: J. C. RUCKDESCHEL
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article BOOK REVIEWS Get access Comprehensive Textbook of Oncology, 2nd Edition, Vols. 1 and 2 A. R. MOOSSA , S. C. Schimpff , M. C. Robson , eds. Baltimore : Williams & Wilkins , 1991 . 1051 pp., illus. $195 JOHN C. RUCKDESCHEL, M.D. JOHN C. RUCKDESCHEL, M.D. Director H. Lee Moffitt Cancer Center12902 Magnolia Dr., Tampa, FL 33612 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 20, 21 October 1992, Pages 1596–1597, https://doi.org/10.1093/jnci/84.20.1596 Published: 21 October 1992
Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population
Authors: Monika Lewinska, Alvaro Santos-Laso, Enara Arretxe, Cristina Alonso, Ekaterina Zhuravleva, Raúl Jiménez-Agüero, Emma Eizaguirre, Mariá Jesús Pareja, Malte Suppli, Filip Krag Knop, Stine Karlsen, Gerda Elisabeth Villadsen, Thomas Decaens, Rocio IR Macias, Bruno Sangro, Jesus M. Banales, Jesper Andersen
Journal: Journal of Hepatology (2020)
Obituary Correction.
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical and Surgical Report of the Boston City Hospital.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mitochondrial oxidative phosphorylation and intracellular glutathione compartmentation during rat liver regeneration
Authors: G VENDEMIALE
Journal: Hepatology (1995)

The rate of mitochondrial oxidative phosphorylation and the cytosolic and mitochondrial total and oxidized glutathione concentrations were studied in regenerating rat livers after partial (70%) hepatectomy. The rate of mitochondrial oxidative phosphorylation progressively decreased during the early prereplicative phase of liver regeneration. This was accompanied by a progressive decrease in mitochondrial, but not cytosolic, glutathione concentration. Twenty-four hours after partial hepatectomy, both the rate of adenosine triphosphate (ATP) synthesis and the amount of mitochondrial glutathione were depressed by 50% with respect to controls (shamoperated animals). During the second replicative phase, both the oxidative phosphorylation rate and mitochondrial glutathione concentration were recovered; however, the kinetics of the recovery were different, being the total amount of mitochondrial glutathione completely restored 48 hours after partial hepatectomy, whereas 72 hours were needed for the recovery of oxidative phosphorylation. The decrease in the rate of oxidative phosphorylation, during the early phase of liver regeneration, appeared to be secondary to the decreased content of the catalytic subunit β-F1 of the ATP synthase complex, which in turn was shown to be linearly related to the decrease of intramitochondrial glutathione. These observations suggest that the two phenomena may be due to the previously reported increased free radical production during the early phase of liver regeneration. The depression of mitochondrial glutathione after partial hepatectomy may play a contributory role in structural and functional alterations of mitochondria occurring in the first retrodifferential phase of liver regeneration.
Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
Authors: Hope S. Rugo, Gabriel N. Hortobagyi, Martine J. Piccart-Gebhart, Howard A. Burris, Mario Campone, Shinzaburo Noguchi, Alejandra T. Perez, Ines Deleu, Mikhail Shtivelband, Louise Provencher, Norikazu Masuda, Shaker R. Dakhil, Ian Anderson, David Chen, Amy Damask, Alan Huang, Robert McDonald, Tanya Taran, Tarek Sahmoud, Jose Baselga
Journal: Journal of Clinical Oncology (2013)

142 Background: Everolimus (EVE) plus exemestane (EXE) more than doubled progression-free survival (PFS) while maintaining quality of life vs EXE alone in postmenopausal women with hormone receptor–positive (HR+), HER2-negative (HER2–) advanced breast cancer (BOLERO-2 phase III; NCT00863655). PFS benefit was seen in all clinically defined subgroups. We evaluated genetic variations of a broad panel of cancer-related genes and explored their correlations with EVE benefit. Methods: Exon sequence and gene copy number variations were analyzed in 182 cancer-related genes by next-generation sequencing (NGS). Correlations with PFS were evaluated using univariate and multivariate Cox models. Results: NGS data (&gt;250x coverage) were successfully generated from archival tumor specimens from 227 patients (NGS population, 157 in EVE + EXE arm and 70 in EXE arm) whose baseline characteristics and clinical outcome were comparable to the trial population (PFS HR = 0.40 and 0.45, respectively). The treatment benefit of EVE + EXE over EXE was maintained in the subgroups defined by each of the 9 genes with a mutation rate &gt;10% (e.g., PIK3CA, FGFR1, CCND1) or when less frequently mutated genes (e.g., PTEN, AKT1) were included in their respective pathways. Patients with 0 or 1 genetic alteration in PI3K or FGFR pathways or CCND1 had a greater treatment effect from EVE (HR = 0.27, 95% CI 0.18-0.41, adjusted by covariates, in 76% of the NGS population), indicating the value of these pathways for predicting sensitivity to EVE in this setting. Conclusions: This is the first global registration trial in which efficacy-predictive biomarkers were explored by correlating broad genetic variations with clinical efficacy. The preliminary results suggest that a large subgroup of patients (76%), defined by minimal genetic variations in the PI3K or FGFR pathways or CCND1, derives the most benefit from EVE therapy (HR = 0.27 vs 0.40 for the full NGS population). These exploratory results and their implication in understanding the interplay of multiple pathways in tumor cells and testing new hypotheses for targeted combination therapies in HR+/HER2– BC will be further investigated. Clinical trial information: NCT00863655.
Sleep position and sudden infant death syndrome
Authors: M. Willinger
Journal: JAMA (1995)

Sudden Infant Death Syndrome (SIDS) is the leading cause of postneonatal infant mortality in the United States. Between 5000 and 6000 infants die with this diagnosis each year, with an incidence in 1992 of 1.2 per 1000 live births.<sup>1</sup>SIDS is defined as the sudden death of an infant younger than 1 year that remains unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of the clinical history.<sup>2</sup>Infants with SIDS die during a critical developmental period, which peaks between 2 and 4 months of age. See also pp 783, 790, and 795. There is evidence from physiologic and pathologic investigations to support the concept that SIDS infants at birth are different from those who survive. However, there are no clinical criteria that distinguish a newborn as high risk. Epidemiologic studies have sought characteristics in the prenatal and
A phase II trial of extended interval port-a-cath (PAC) flushes.
Authors: M. A. Janjua, F. Kayali, D. Jain, C. Salvador, G. Rabinowits, D. A. Laber, G. H. Kloecker
Journal: Journal of Clinical Oncology (2010)

e19635 Background: Subcutaneous PAC has become more popular over the past decade. Complications of PAC placement and maintenance occur in 5-15%. Few studies have commented on the interval between catheter accession, flushing, and subsequent complication. As the number of patients retaining their ports for extended periods of time increases; a safe, cost effective, and convenient catheter maintenance protocol has not been defined. Looking at our institution the cost of each flush is approx $50/-, not taking into consideration patient cost and travel time every 4 weeks. Methods: Patients with functional PAC's are enrolled after completing curative intent therapy. PAC's are flushed in 3 months intervals for a total of 12 months. The study plans to close one year after the last patient is enrolled. The end points of the study are time to port complication and port failure requiring removal. The costs of port flushes at our institution will be evaluated based on Medicare charges. Results: Accrual started 5/09-11/09 at the time of interim analysis with 50% patient accrual goal met in less than 6 months. PAC was placed mostly by interventional radiology. 32 were consented with 3 screen failures. 29 were actively enrolled, median age 58yrs (33-74), 22 females. The most common malignancies are lung cancer (45%) and breast cancer (28%). Six patients became ineligible for continuation, due to disease recurrence and non-compliance 17 patients have had at least 2 flushes without complications. Within 6 months 36 flushes were completed according to study protocol. Conclusions: In this interim analysis, our study showed an excelled accrual due to patients' readiness to enroll. In the 23 presently active patients no significant PAC complication was seen. The approach appears cost effective. 36 flushes in six months period were charged $1,800/-, which is half of the monthly interval standard cost. Long-term follow-up is needed to evaluate cost effectiveness and safety. No significant financial relationships to disclose.
BRITISH CHOLERA MICROBES.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Looking at Cancer
Authors: June Goffinet
Journal: CA A Cancer Journal for Clinicians (1976)

California) call attention to a high local failure rate in patients treated with the now standard inverted â€oe¿ Yâ€• ab dominal portals.They describe a safe and apparently effec tive technique that allows irradiation of the whole abdomen, with partial shielding of the liver and kidneys.Full thickness lead blocks protect the right hepatic lobe during the initial